GB9215633D0 - Novel treatment - Google Patents

Novel treatment

Info

Publication number
GB9215633D0
GB9215633D0 GB929215633A GB9215633A GB9215633D0 GB 9215633 D0 GB9215633 D0 GB 9215633D0 GB 929215633 A GB929215633 A GB 929215633A GB 9215633 A GB9215633 A GB 9215633A GB 9215633 D0 GB9215633 D0 GB 9215633D0
Authority
GB
United Kingdom
Prior art keywords
novel treatment
novel
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB929215633A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to GB929215633A priority Critical patent/GB9215633D0/en
Publication of GB9215633D0 publication Critical patent/GB9215633D0/en
Priority to PCT/GB1993/001539 priority patent/WO1994002150A1/en
Priority to EP93917883A priority patent/EP0651642A1/en
Priority to AU47143/93A priority patent/AU4714393A/en
Priority to JP6504294A priority patent/JPH07509456A/ja
Priority to CN93116874A priority patent/CN1043610C/zh
Priority to MX9304435A priority patent/MX9304435A/es
Priority to ZA935339A priority patent/ZA935339B/xx
Priority to TW082105967A priority patent/TW258663B/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB929215633A 1992-07-23 1992-07-23 Novel treatment Pending GB9215633D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GB929215633A GB9215633D0 (en) 1992-07-23 1992-07-23 Novel treatment
PCT/GB1993/001539 WO1994002150A1 (en) 1992-07-23 1993-07-21 Use of 1,3-dicyclopropymethyl-8-amino-xanthine for the treatment and prevention of type ii diabetes mellitus and obesity
EP93917883A EP0651642A1 (en) 1992-07-23 1993-07-21 Use of 1,3-dicyclopropymethyl-8-amino-xanthine for the treatment and prevention of type ii diabetes mellitus and obesity
AU47143/93A AU4714393A (en) 1992-07-23 1993-07-21 Use of 1,3-dicyclopropymethyl-8-amino-xanthine for the treatment and prevention of type ii diabetes mellitus and obesity
JP6504294A JPH07509456A (ja) 1992-07-23 1993-07-21 ２型糖尿病および肥満の治療および予防のための１，３−ジシクロプロピメチル−８−アミノ−キサンチンの使用
CN93116874A CN1043610C (zh) 1992-07-23 1993-07-22 新的治疗剂
MX9304435A MX9304435A (es) 1992-07-23 1993-07-22 Compuesto y composicion farmaceutica para el tratamiento y la profilaxis de la obesidad o para el tratamiento de la diabetes del tipo ii.
ZA935339A ZA935339B (en) 1992-07-23 1993-07-23 Anti-obesity agent
TW082105967A TW258663B (zh) 1992-07-23 1993-07-27

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929215633A GB9215633D0 (en) 1992-07-23 1992-07-23 Novel treatment

Publications (1)

Publication Number Publication Date
GB9215633D0 true GB9215633D0 (en) 1992-09-09

Family

ID=10719151

Family Applications (1)

Application Number Title Priority Date Filing Date
GB929215633A Pending GB9215633D0 (en) 1992-07-23 1992-07-23 Novel treatment

Country Status (9)

Country Link
EP (1) EP0651642A1 (zh)
JP (1) JPH07509456A (zh)
CN (1) CN1043610C (zh)
AU (1) AU4714393A (zh)
GB (1) GB9215633D0 (zh)
MX (1) MX9304435A (zh)
TW (1) TW258663B (zh)
WO (1) WO1994002150A1 (zh)
ZA (1) ZA935339B (zh)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783408A (en) * 1995-06-07 1998-07-21 Hamilton; Bradford S. Method for screening potential anti-obesity agents
ATE353900T1 (de) * 2001-02-24 2007-03-15 Boehringer Ingelheim Pharma Xanthinderivate, deren herstellung und deren verwendung als arzneimittel
ATE388951T1 (de) * 2001-07-03 2008-03-15 Novo Nordisk As Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
US6869947B2 (en) 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
JP2005509603A (ja) * 2001-09-19 2005-04-14 ノボ　ノルディスク　アクティーゼルスカブ Ｄｐｐ−ｉｖ酵素の阻害剤であるヘテロ環化合物
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (de) * 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
MXPA06002521A (es) 2003-09-05 2006-06-20 Altana Pharma Ag Uso de inhibidores de pde4 para el tratamiento de diabetes mellitus.
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EA015382B1 (ru) 2005-03-08 2011-08-30 Никомед Гмбх Применение рофлумиласта для лечения сахарного диабета типа 2
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
KR102668834B1 (ko) 2009-11-27 2024-05-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
KR20230051307A (ko) 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EA030121B1 (ru) 2011-07-15 2018-06-29 Бёрингер Ингельхайм Интернациональ Гмбх Замещенные хиназолины, их получение и их применение в фармацевтических композициях
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds

Also Published As

Publication number Publication date
CN1114880A (zh) 1996-01-17
MX9304435A (es) 1994-04-29
CN1043610C (zh) 1999-06-16
JPH07509456A (ja) 1995-10-19
WO1994002150A1 (en) 1994-02-03
AU4714393A (en) 1994-02-14
EP0651642A1 (en) 1995-05-10
ZA935339B (en) 1995-01-18
TW258663B (zh) 1995-10-01

Similar Documents

Publication Publication Date Title
GB9215633D0 (en) Novel treatment
GB9208339D0 (en) Treatment composition
GB9127150D0 (en) Novel treatment
GB9226860D0 (en) Novel treatment
GB9211148D0 (en) Novel treatment
GB9203039D0 (en) Treatment
GB9225860D0 (en) Novel treatment
GB9226957D0 (en) Novel treatment
GB9226958D0 (en) Produktionsaktieselskab) novel treatment
GB9308802D0 (en) Treatment
AP9300527A0 (en) Novel treatment
GB9203637D0 (en) Novel treatment
GB9225859D0 (en) Novel treatment
GB9225862D0 (en) Novel treatment
GB9225957D0 (en) Novel treatment
GB9225959D0 (en) Novel treatment
GB9225961D0 (en) Novel treatment
GB9225963D0 (en) Novel treatment
GB9225964D0 (en) Novel treatment
GB9225956D0 (en) Novel treatment
GB9225948D0 (en) Novel treatment
GB9225881D0 (en) Novel treatment
GB9225863D0 (en) Novel treatment
AP9200456A0 (en) Novel treatment
GB9225861D0 (en) Novel treatment